Autopsy report · NCT06206746

The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System

“Business decision by sponsor to terminate the study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 2 years 5 months before it stopped.
• 93 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

May Health

Sponsor type

Industry

Conditions

Polycystic Ovary Syndrome; Infertility, Female

Interventions

May Health System

Participants

93

Sites

19

Countries

United States

Trials that died the same way

• Study of Viziatek ISL™ Refractive Phakic Intra Sulcus Lens for Refraction Adjustment in Blind Volunteers
  “Sponsor decision to terminate the study” (95% match in meaning)
• Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
  “Sponsor decision to terminate study.” (93% match in meaning)
• Natural History Study of Patients With Methylmalonic Acidemia and Propionic Acidemia
  “The decision to terminate the study was based on business considerations by the Sponsor.” (92% match in meaning)
• Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
  “Sponsor decided to terminate the study” (92% match in meaning)
• A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
  “Sponsor decision to early terminate the study” (92% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.